Roche Holding AG (OTCMKTS:RHHBY) Holdings Boosted by Saratoga Research & Investment Management

Saratoga Research & Investment Management grew its position in shares of Roche Holding AG (OTCMKTS:RHHBYFree Report) by 6.9% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 2,458,918 shares of the company’s stock after purchasing an additional 158,482 shares during the quarter. Roche makes up about 3.6% of Saratoga Research & Investment Management’s holdings, making the stock its 10th largest position. Saratoga Research & Investment Management’s holdings in Roche were worth $78,489,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Pacer Advisors Inc. grew its holdings in shares of Roche by 1,937.5% during the fourth quarter. Pacer Advisors Inc. now owns 1,099,659 shares of the company’s stock worth $39,841,000 after buying an additional 1,045,687 shares during the last quarter. OLD National Bancorp IN grew its holdings in shares of Roche by 2.0% during the third quarter. OLD National Bancorp IN now owns 251,843 shares of the company’s stock worth $8,619,000 after buying an additional 4,956 shares during the last quarter. Hikari Power Ltd grew its holdings in shares of Roche by 0.8% during the fourth quarter. Hikari Power Ltd now owns 237,820 shares of the company’s stock worth $8,616,000 after buying an additional 2,000 shares during the last quarter. Altrius Capital Management Inc grew its holdings in shares of Roche by 2.9% during the fourth quarter. Altrius Capital Management Inc now owns 176,001 shares of the company’s stock worth $6,377,000 after buying an additional 4,939 shares during the last quarter. Finally, Yousif Capital Management LLC grew its holdings in shares of Roche by 6.9% during the fourth quarter. Yousif Capital Management LLC now owns 99,124 shares of the company’s stock worth $3,599,000 after buying an additional 6,440 shares during the last quarter.

Roche Stock Performance

Shares of OTCMKTS RHHBY traded down $0.24 during trading on Friday, hitting $34.67. 1,218,740 shares of the company traded hands, compared to its average volume of 2,385,903. Roche Holding AG has a 1 year low of $29.20 and a 1 year high of $39.92. The company has a 50-day moving average price of $32.35 and a 200-day moving average price of $33.20. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.75.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on RHHBY. Argus restated a “hold” rating on shares of Roche in a research report on Monday, March 4th. Deutsche Bank Aktiengesellschaft upgraded shares of Roche from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. Finally, The Goldman Sachs Group began coverage on shares of Roche in a research report on Thursday, May 30th. They issued a “sell” rating for the company. Two analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $40.00.

Read Our Latest Stock Report on RHHBY

Roche Company Profile

(Free Report)

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.

Featured Stories

Want to see what other hedge funds are holding RHHBY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roche Holding AG (OTCMKTS:RHHBYFree Report).

Institutional Ownership by Quarter for Roche (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.